quantitative hek293 genomic dna reference standard (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
96
Structured Review
ATCC
quantitative hek293 genomic dna reference standard
Quantitative Hek293 Genomic Dna Reference Standard, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 25 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantitative+hek293+genomic+dna+reference+standard/Quantitative+HEK-293+Genomic+DNA/10__1016_slash_j__ymthe__2024__04__020-21115-27-26
Average 96 stars, based on 25 article reviews
Quantitative Hek293 Genomic Dna Reference Standard, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 25 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantitative+hek293+genomic+dna+reference+standard/Quantitative+HEK-293+Genomic+DNA/10__1016_slash_j__ymthe__2024__04__020-21115-27-26
Average 96 stars, based on 25 article reviews
quantitative hek293 genomic dna reference standard - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Real-time Polymerase Chain Reaction:Article Title: ASGCT 27th Annual Meeting Abstracts Article Snippet: Atidarsagene Autotemcel (Hematopoietic Stem Cell GeneTherapy) Preserves Cognitive and Motor Development in Metachromatic Leukodystrophy with up to 12 Years Follow-Up Valeria Calbi1, Francesca Fumagalli1, Fabiola De Mattia1, Alberto Zambon1, Vera Gallo1, Salvatore Recupero1, Elena Sophia Fratini2, Alessia Ippolito1, Francesca Ciotti1, Maddalena Fraschini1, Marina Sarzana1, Stefano Scarparo1, Eugenio Montini1, Sara Locatelli1, Marcella Facchini1, Alessandra Clerici1, Francesco Morena3, Sabata Martino3, Muska Yarzi4, Sean L. Moro5, Andrew Shenker6, Jean Brooks4, Alan Richardson4, Laura Campbell4, Alessandro Aiuti2 1San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy,2San Raffaele Telethon Institute for Gene Therapy (SR-Tiget); Vita Salute San Raffaele University, Milan, Italy,3University of Perugia, Perugia, Italy,4Orchard Therapeutics, London, United Kingdom,5Orchard Therapeutics, Boston, MA,6Clinical Consultant, Pennington, NJ Introduction: Metachromatic leukodystrophy (MLD) is a rare neurometabolic disorder caused by deficiency of arylsulfatase A (ARSA), leading to accumulation of sulfatides in the central and peripheral nervous systems, and subsequently progressive demyelination, neurodegeneration, loss of all motor and cognitive skills and early death.. Methods: We present long-term results from an integrated analysis of 39 patients with early-onset MLD (19 late infantile, 20 early juvenile) treated with autologous ex vivo hematopoietic stem cell gene therapy (atidarsagene autotemcel, “arsa-cel”) across two prospective clinical trials (n=30) and expanded access frameworks (n=9).. Arsa-cel consists of autologous CD34+ cells transduced ex vivo with a lentiviral vector encoding for the human ARSA gene. Quantitation Assay:Article Title: ASGCT 27th Annual Meeting Abstracts Article Snippet: Atidarsagene Autotemcel (Hematopoietic Stem Cell GeneTherapy) Preserves Cognitive and Motor Development in Metachromatic Leukodystrophy with up to 12 Years Follow-Up Valeria Calbi1, Francesca Fumagalli1, Fabiola De Mattia1, Alberto Zambon1, Vera Gallo1, Salvatore Recupero1, Elena Sophia Fratini2, Alessia Ippolito1, Francesca Ciotti1, Maddalena Fraschini1, Marina Sarzana1, Stefano Scarparo1, Eugenio Montini1, Sara Locatelli1, Marcella Facchini1, Alessandra Clerici1, Francesco Morena3, Sabata Martino3, Muska Yarzi4, Sean L. Moro5, Andrew Shenker6, Jean Brooks4, Alan Richardson4, Laura Campbell4, Alessandro Aiuti2 1San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy,2San Raffaele Telethon Institute for Gene Therapy (SR-Tiget); Vita Salute San Raffaele University, Milan, Italy,3University of Perugia, Perugia, Italy,4Orchard Therapeutics, London, United Kingdom,5Orchard Therapeutics, Boston, MA,6Clinical Consultant, Pennington, NJ Introduction: Metachromatic leukodystrophy (MLD) is a rare neurometabolic disorder caused by deficiency of arylsulfatase A (ARSA), leading to accumulation of sulfatides in the central and peripheral nervous systems, and subsequently progressive demyelination, neurodegeneration, loss of all motor and cognitive skills and early death.. Methods: We present long-term results from an integrated analysis of 39 patients with early-onset MLD (19 late infantile, 20 early juvenile) treated with autologous ex vivo hematopoietic stem cell gene therapy (atidarsagene autotemcel, “arsa-cel”) across two prospective clinical trials (n=30) and expanded access frameworks (n=9).. Arsa-cel consists of autologous CD34+ cells transduced ex vivo with a lentiviral vector encoding for the human ARSA gene. |